Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014;58(3):1615-21.
doi: 10.1128/AAC.01786-13. Epub 2013 Dec 23.

Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects

Podjanee Jittamala  1 , Sasithon Pukrittayakamee, Joel Tarning, Niklas Lindegardh, Warunee Hanpithakpong, Walter Robert John Taylor, Saranath Lawpoolsri, Prakaykaew Charunwattana, Salwaluk Panapipat, Nicholas J White, Nicholas P J Day
Affiliations
Randomized Controlled Trial

Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects

Podjanee Jittamala et al. Antimicrob Agents Chemother. 2014.

Abstract

Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavorable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and nonobese healthy subjects. A single-dose, randomized, two-sequence crossover study was conducted in 12 obese and 12 nonobese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening washout period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a noncompartmental approach. The median (range) body mass indexes (BMIs) for obese subjects were 33.8 kg/m(2) (30.8 to 43.2) and 22.2 (18.8 to 24.2) for nonobese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and nonobese subjects for both 75-mg and 150-mg doses. Both doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects, there was no significant difference in the exposure of oseltamivir carboxylate between the obese and nonobese groups. Standard dosing is appropriate for obese subjects. (The study was registered at ClinicalTrials.gov under registration no. NCT 01049763.).

Trial registration: ClinicalTrials.gov NCT01049763.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Mean (±standard deviation [SD]) concentration-time profiles of oseltamivir (A and B) and oseltamivir carboxylate (C and D) stratified by dose regimen (75-mg [A and C] or 150-mg [B and D] oseltamivir dose) in nonobese (solid lines) and obese (dashed lines) healthy Thai subjects.
FIG 2
FIG 2
Total dose-normalized exposure of oseltamivir (A) and oseltamivir carboxylate (B) stratified by dose regimen in nonobese and obese healthy Thai subjects. The long horizontal bars indicate median values, and the error bars indicate the interquartile range.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO 2006. Rapid advice guidelines on pharmacological management of human infected with avian influenza A (H5N1) virus. World Health Organization, Geneva, Switzerland: http://www.who.int/influenza/resources/documents/pharmacological_managem...
    1. WHO 2009. Pharmacological management of pandemic influenza A (H1N1) 2009 and other influenza viruses. World Health Organization; Geneva, Switzerland: http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_p... - PubMed
    1. CDC 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza. Recommendations of advisory committee on immunization practice (ACIP). Centers for Disease Control and Prevention, Atlanta, GA: http://www.cdc.gov/mmwr/pdf/rr/rr6001.pdf - PubMed
    1. Falagas ME, Koletsi PK, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Rello J. 2010. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 65:1330–1346. 10.1093/jac/dkq158 - DOI - PubMed
    1. Davies BE. 2010. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother. 65(Suppl 2):ii5–10. 10.1093/jac/dkq015 - DOI - PMC - PubMed

Publication types

Associated data

LinkOut - more resources